

Henry J Kaminski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6317056/publications.pdf>

Version: 2024-02-01

164
papers

7,804
citations

57631

44
h-index

60497

81
g-index

169
all docs

169
docs citations

169
times ranked

5917
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	36
2	Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurology, The, 2022, 21, 189-202.	4.9	41
3	Impact of the Covid-19 epidemic on a US sample of patients with myasthenia gravis. Therapeutic Advances in Rare Disease, 2022, 3, 263300402210826.	0.3	3
4	Corticosteroid Treatment-Resistance in Myasthenia Gravis. Frontiers in Neurology, 2022, 13, 886625.	1.1	9
5	Reduced plasmablast frequency is associated with seronegative myasthenia gravis. Muscle and Nerve, 2021, 63, 577-585.	1.0	2
6	Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (<sc>MG–CE</sc>). Muscle and Nerve, 2021, 64, 270-276.	1.0	16
7	Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease. Orphanet Journal of Rare Diseases, 2021, 16, 457.	1.2	8
8	Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30649-30660.	3.3	33
9	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurology, The, 2020, 19, 970-971.	4.9	85
10	Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America. BMJ Open, 2020, 10, e037909.	0.8	12
11	The Presence of Survivin on B Cells from Myasthenia Gravis Patients and the Potential of an Antibody to a Modified Survivin Peptide to Alleviate Weakness in an Animal Model. Journal of Immunology, 2020, 205, 1743-1751.	0.4	3
12	Monoclonal Antibody-Based Therapies for Myasthenia Gravis. BioDrugs, 2020, 34, 557-566.	2.2	22
13	Gender differences in quality of life among patients with myasthenia gravis in China. Health and Quality of Life Outcomes, 2020, 18, 296.	1.0	25
14	Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study. Muscle and Nerve, 2020, 62, 261-266.	1.0	15
15	Complement Inhibitor Therapy for Myasthenia Gravis. Frontiers in Immunology, 2020, 11, 917.	2.2	39
16	Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology, 2020, 95, e755-e766.	1.5	17
17	Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis. JAMA Neurology, 2020, 77, 582.	4.5	126
18	Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment. Muscle and Nerve, 2019, 60, 707-715.	1.0	56

#	ARTICLE	IF	CITATIONS
19	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. <i>Lancet Neurology</i> , The, 2019, 18, 259-268.	4.9	139
20	Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 13, 484-492.	1.8	37
21	A Neurologist's Perspective on Understanding Myasthenia Gravis. <i>Thoracic Surgery Clinics</i> , 2019, 29, 133-141.	0.4	6
22	Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry. <i>Muscle and Nerve</i> , 2018, 58, 90-98.	1.0	31
23	Ocular Myasthenia. <i>Neurologic Clinics</i> , 2018, 36, 241-251.	0.8	50
24	Clinical trials for myasthenia gravis: a historical perspective. <i>Annals of the New York Academy of Sciences</i> , 2018, 1413, 5-10.	1.8	5
25	Acetylcholine receptor antibody-mediated animal models of myasthenia gravis and the role of complement. <i>Annals of the New York Academy of Sciences</i> , 2018, 1413, 136-142.	1.8	13
26	Treatment of Myasthenia Gravis. , 2018, , 169-187.		4
27	Emerging Therapeutics for Myasthenia Gravis. , 2018, , 319-333.		0
28	Clinical Trial Design for Myasthenia Gravis. , 2018, , 335-344.		0
29	Gender differences in prednisone adverse effects. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e507.	3.1	25
30	Pearls & Oysters: Pembrolizumab-induced myasthenia gravis. <i>Neurology</i> , 2018, 91, e1365-e1367.	1.5	26
31	MicroRNA and mRNA expression associated with ectopic germinal centers in thymus of myasthenia gravis. <i>PLoS ONE</i> , 2018, 13, e0205464.	1.1	13
32	Advances in autoimmune myasthenia gravis management. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 573-588.	1.4	40
33	Histopathology of thymectomy specimens from the MGTX-trial: Entropy analysis as strategy to quantify spatial heterogeneity of lymphoid follicle and fat distribution. <i>PLoS ONE</i> , 2018, 13, e0197435.	1.1	7
34	Inpatient cost analysis for treatment of myasthenia gravis. <i>Muscle and Nerve</i> , 2017, 56, 1114-1118.	1.0	11
35	Concurrent Paraspinal Myopathy and Myasthenia Gravis. <i>Journal of Clinical Neuromuscular Disease</i> , 2017, 18, 218-222.	0.3	5
36	Ablation of IL-17 expression moderates experimental autoimmune myasthenia gravis disease severity. <i>Cytokine</i> , 2017, 96, 279-285.	1.4	22

#	ARTICLE	IF	CITATIONS
37	Rare disease levels of evidence. <i>Neurology</i> , 2017, 89, 988-989.	1.5	0
38	Shortage of generic neurologic therapeutics. <i>Neurology</i> , 2017, 89, 2431-2437.	1.5	3
39	The Role of Osteopontin and Its Gene on Glucocorticoid Response in Myasthenia Gravis. <i>Frontiers in Neurology</i> , 2017, 8, 230.	1.1	16
40	Cognitive-Behavioral Therapy for Psychiatric Comorbidity in a Case of Muscle-Specific Kinase—Positive Myasthenia Gravis. primary care companion for CNS disorders, <i>The</i> , 2017, 19, .	0.2	0
41	Randomized trial of thymectomy in myasthenia gravis. <i>Journal of Thoracic Disease</i> , 2016, 8, E1782-E1783.	0.6	21
42	Differential RNA Expression Profile of Skeletal Muscle Induced by Experimental Autoimmune Myasthenia Gravis in Rats. <i>Frontiers in Physiology</i> , 2016, 7, 524.	1.3	7
43	Seronegative Myasthenia Gravis—A Vanishing Disorder?. <i>JAMA Neurology</i> , 2016, 73, 1055.	4.5	14
44	Thymectomy is safe for myasthenia gravis patients: Analysis of the NSQIP database. <i>Muscle and Nerve</i> , 2016, 53, 370-374.	1.0	9
45	<i>GR</i> gene polymorphism is associated with inter-subject variability in response to glucocorticoids in patients with myasthenia gravis. <i>European Journal of Neurology</i> , 2016, 23, 1372-1379.	1.7	25
46	Randomized Trial of Thymectomy in Myasthenia Gravis. <i>New England Journal of Medicine</i> , 2016, 375, 511-522.	13.9	695
47	Randomized Trial of Thymectomy in Myasthenia Gravis. <i>New England Journal of Medicine</i> , 2016, 375, 2005-2007.	13.9	39
48	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. <i>Muscle and Nerve</i> , 2016, 53, 165-168.	1.0	24
49	Elevated plasma interleukin-17A in a subgroup of Myasthenia Gravis patients. <i>Cytokine</i> , 2016, 78, 44-46.	1.4	40
50	Two steps forward, one step back: Mycophenolate mofetil treatment for myasthenia gravis in the united states. <i>Muscle and Nerve</i> , 2015, 51, 635-637.	1.0	18
51	How clinical trials of myasthenia gravis can inform pre-clinical drug development. <i>Experimental Neurology</i> , 2015, 270, 78-81.	2.0	9
52	A Genome-Wide Association Study of Myasthenia Gravis. <i>JAMA Neurology</i> , 2015, 72, 396.	4.5	139
53	Editorial: Special issue on standardization of preclinical evaluation of animal models for myasthenia gravis. <i>Experimental Neurology</i> , 2015, 270, 1-2.	2.0	4
54	RNA Expression Analysis of Passive Transfer Myasthenia Supports Extraocular Muscle as a Unique Immunological Environment. , 2014, 55, 4348.		16

#	ARTICLE	IF	CITATIONS
55	Myeloid-Derived Suppressor Cells as a Potential Therapy for Experimental Autoimmune Myasthenia Gravis. <i>Journal of Immunology</i> , 2014, 193, 2127-2134.	0.4	54
56	<i>Pitx2</i> , an Atrial Fibrillation Predisposition Gene, Directly Regulates Ion Transport and Intercalated Disc Genes. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 23-32.	5.1	103
57	The third leg of neurology training. <i>Neurology</i> , 2014, 83, 1778-1779.	1.5	0
58	Neuromuscular junction as Achilles' heel: Yet another autoantibody?. <i>Neurology</i> , 2014, 82, 1942-1943.	1.5	5
59	Targeting therapy to the neuromuscular junction: Proof of concept. <i>Muscle and Nerve</i> , 2014, 49, 749-756.	1.0	24
60	Survivin as a Potential Mediator to Support Autoreactive Cell Survival in Myasthenia Gravis: A Human and Animal Model Study. <i>PLoS ONE</i> , 2014, 9, e102231.	1.1	31
61	Serum Metabolomic Response of Myasthenia Gravis Patients to Chronic Prednisone Treatment. <i>PLoS ONE</i> , 2014, 9, e102635.	1.1	13
62	Autoantibody Testing of Autoimmune Neuromuscular Junction, Hyperexcitability, and Muscle Disorders. , 2014, , 69-77.		0
63	Cell surface complement regulators moderate experimental myasthenia gravis pathology. <i>Muscle and Nerve</i> , 2013, 47, 33-40.	1.0	17
64	Importance and hurdles to drug discovery for neurological disease. <i>Annals of Neurology</i> , 2013, 74, 441-446.	2.8	15
65	Genomic Profiling Reveals <i>Pitx2</i> Controls Expression of Mature Extraocular Muscle Contraction-Related Genes. , 2012, 53, 1821.		20
66	Mexiletine for Treatment of Myotonia. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1377.	3.8	17
67	The role of complement in experimental autoimmune myasthenia gravis. <i>Annals of the New York Academy of Sciences</i> , 2012, 1274, 127-132.	1.8	16
68	Biomarker development for myasthenia gravis. <i>Annals of the New York Academy of Sciences</i> , 2012, 1275, 101-106.	1.8	20
69	Implementing clinical trials on an international platform: Challenges and perspectives. <i>Journal of the Neurological Sciences</i> , 2012, 313, 1-6.	0.3	38
70	Protective effect of scFv α CDAF fusion protein on the complement attack to acetylcholine receptor: A possible option for treatment of myasthenia gravis. <i>Muscle and Nerve</i> , 2012, 45, 668-675.	1.0	13
71	Recommendations for myasthenia gravis clinical trials. <i>Muscle and Nerve</i> , 2012, 45, 909-917.	1.0	122
72	Natural History of Myasthenia Gravis. , 2012, , 90-107.		11

#	ARTICLE	IF	CITATIONS
73	Pitx2 regulates myosin heavy chain isoform expression and multi-innervation in extraocular muscle. <i>Journal of Physiology</i> , 2011, 589, 4601-4614.	1.3	25
74	Factors contributing to failure of neuromuscular transmission in myasthenia gravis and the special case of the extraocular muscles. <i>Annals of the New York Academy of Sciences</i> , 2011, 1233, 26-33.	1.8	18
75	Treatment of Myasthenia Gravis. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 89-96.	2.0	55
76	Outcome of plasmapheresis in myasthenia gravis: Delayed therapy is not favorable. <i>Muscle and Nerve</i> , 2011, 43, 578-584.	1.0	19
77	Practice parameters and focusing research: Plasma exchange for myasthenia gravis. <i>Muscle and Nerve</i> , 2011, 43, 625-626.	1.0	15
78	Epstein-barr virus: Trigger for autoimmunity?. <i>Annals of Neurology</i> , 2010, 67, NA-NA.	2.8	4
79	Comparative analysis of therapeutic options used for myasthenia gravis. <i>Annals of Neurology</i> , 2010, 68, 797-805.	2.8	135
80	Myosin Heavy Chain Expression in Mouse Extraocular Muscle: More Complex Than Expected. , 2010, 51, 6355.		46
81	Perimysial Fibroblasts of Extraocular Muscle, as Unique as the Muscle Fibers. , 2010, 51, 192.		24
82	An Altered Phenotype in a Conditional Knockout of Pitx2 in Extraocular Muscle. , 2009, 50, 4531.		33
83	Erratum to "The MGTX experience: Challenges in planning and executing an international, multicenter clinical trial" [J. Neuroimmunol. 2012(2008)80:84]. <i>Journal of Neuroimmunology</i> , 2009, 217, 103.	1.1	1
84	Novel complement inhibitor limits severity of experimentally myasthenia gravis. <i>Annals of Neurology</i> , 2009, 65, 67-75.	2.8	83
85	Treatment of Myasthenia Gravis. , 2009, , 157-173.		1
86	<i>Status of the Thymectomy Trial for Nonthymomatous Myasthenia Gravis Patients Receiving Prednisone</i>. <i>Annals of the New York Academy of Sciences</i> , 2008, 1132, 344-347.	1.8	69
87	<i>Extraocular Muscle Susceptibility to Myasthenia Gravis</i>. <i>Annals of the New York Academy of Sciences</i> , 2008, 1132, 220-224.	1.8	61
88	The MGTX experience: Challenges in planning and executing an international, multicenter clinical trial. <i>Journal of Neuroimmunology</i> , 2008, 201-202, 80-84.	1.1	28
89	Effect of complement and its regulation on myasthenia gravis pathogenesis. <i>Expert Review of Clinical Immunology</i> , 2008, 4, 43-52.	1.3	34
90	Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. <i>Journal of the Neurological Sciences</i> , 2008, 264, 106-111.	0.3	69

#	ARTICLE	IF	CITATIONS
91	Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. <i>Current Opinion in Neurology</i> , 2008, 21, 8-15.	1.8	68
92	C5 complement inhibition contributes to increased proliferative activity and antigen specific recall response in experimentally acquired myasthenia gravis (EAMG). <i>FASEB Journal</i> , 2008, 22, 1074.10.	0.2	0
93	Monocular visual deprivation in macaque monkeys: a profile in the gene expression of lateral geniculate nucleus by laser capture microdissection. <i>Molecular Vision</i> , 2008, 14, 1401-13.	1.1	11
94	Evidence report: The medical treatment of ocular myasthenia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2007, 68, 2144-2149.	1.5	132
95	Anti-C5 Antibody Treatment Ameliorates Weakness in Experimentally Acquired Myasthenia Gravis. <i>Journal of Immunology</i> , 2007, 179, 8562-8567.	0.4	78
96	Ocular myasthenia revisited: Insights from pseudo-internuclear ophthalmoplegia. <i>Journal of Neurology</i> , 2007, 254, 1569-1574.	1.8	28
97	A genetic model for muscle "eye" brain disease in mice lacking protein O-mannose 1,2-N-acetylglucosaminyltransferase (POMGnT1). <i>Mechanisms of Development</i> , 2006, 123, 228-240.	1.7	115
98	Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. <i>Experimental Neurology</i> , 2006, 202, 287-293.	2.0	47
99	Temporal and spatial mRNA expression patterns of TGF- β 1, 2, 3 and T β RI, II, III in skeletal muscles of mdx mice. <i>Neuromuscular Disorders</i> , 2006, 16, 32-38.	0.3	83
100	Myasthenia gravis: past, present, and future. <i>Journal of Clinical Investigation</i> , 2006, 116, 2843-2854.	3.9	515
101	Ocular Myasthenia. <i>Neurologist</i> , 2006, 12, 231-239.	0.4	47
102	Distinctive morphological and gene/protein expression signatures during myogenesis in novel cell lines from extraocular and hindlimb muscle. <i>Physiological Genomics</i> , 2006, 24, 264-275.	1.0	41
103	Molecular architecture of the neuromuscular junction. <i>Muscle and Nerve</i> , 2006, 33, 445-461.	1.0	132
104	Adverse effects of myasthenia gravis on rat phrenic diaphragm contractile performance. <i>Journal of Applied Physiology</i> , 2004, 97, 895-901.	1.2	13
105	Pathophysiology of Myasthenia Gravis. <i>Seminars in Neurology</i> , 2004, 24, 21-30.	0.5	98
106	Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. <i>Experimental Neurology</i> , 2004, 189, 333-342.	2.0	68
107	Susceptibility of Ocular Tissues to Autoimmune Diseases. <i>Annals of the New York Academy of Sciences</i> , 2003, 998, 362-374.	1.8	49
108	Development of a Thymectomy Trial in Nonthymomatous Myasthenia Gravis Patients Receiving Immunosuppressive Therapy. <i>Annals of the New York Academy of Sciences</i> , 2003, 998, 473-480.	1.8	63

#	ARTICLE	IF	CITATIONS
109	Preoperative preparation of patients with myasthenia gravis forestalls postoperative respiratory complications after thymectomy. <i>Annals of Thoracic Surgery</i> , 2003, 75, 1068.	0.7	10
110	Thymectomy for myasthenia gravis: evaluation requires controlled prospective studies. <i>Annals of Thoracic Surgery</i> , 2003, 76, 1-3.	0.7	27
111	Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. <i>Neuromuscular Disorders</i> , 2003, 13, 223-235.	0.3	85
112	Constitutive properties, not molecular adaptations, mediate extraocular muscle sparing in dystrophicmdxmice. <i>FASEB Journal</i> , 2003, 17, 1-27.	0.2	66
113	Molecular Organization of the Extraocular Muscle Neuromuscular Junction: Partial Conservation of and Divergence from the Skeletal Muscle Prototype. , 2003, 44, 1918.		37
114	Treatment of Myasthenia Gravis. , 2003, , 197-221.		8
115	Myasthenia Gravis: An Illustrated History. <i>Archives of Neurology</i> , 2003, 60, 1487.	4.9	0
116	A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. <i>Human Molecular Genetics</i> , 2002, 11, 263-272.	1.4	368
117	Problems in the evaluation of thymectomy for myasthenia gravis. <i>Annals of Thoracic Surgery</i> , 2002, 73, 1027-1028.	0.7	9
118	Electrodiagnostic approach to the patient with suspected neuromuscular junction disorder. <i>Neurologic Clinics</i> , 2002, 20, 557-586.	0.8	25
119	Neuromuscular Manifestations of Endocrine Disorders. <i>Neurologic Clinics</i> , 2002, 20, 35-58.	0.8	29
120	Differential Susceptibility of the Ocular Motor System to Disease. <i>Annals of the New York Academy of Sciences</i> , 2002, 956, 42-54.	1.8	57
121	Extraocular Muscle Fatigue. <i>Annals of the New York Academy of Sciences</i> , 2002, 956, 397-398.	1.8	8
122	Nitric Oxide and cGMP Modulation of Extraocular Muscle Contraction. <i>Annals of the New York Academy of Sciences</i> , 2002, 956, 399-400.	1.8	2
123	Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. <i>Journal of Clinical Investigation</i> , 2002, 110, 1269-1274.	3.9	62
124	Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. <i>Journal of Clinical Investigation</i> , 2002, 110, 1269-1274.	3.9	58
125	Nitric oxide: biologic effects on muscle and role in muscle diseases. <i>Neuromuscular Disorders</i> , 2001, 11, 517-524.	0.3	64
126	Thymectomy for myasthenia gravis in older patients. <i>Journal of the American College of Surgeons</i> , 2001, 193, 340-341.	0.2	12

#	ARTICLE	IF	CITATIONS
127	Nitric oxide synthase expression and effects of nitric oxide modulation on contractility of rat extraocular muscle. <i>FASEB Journal</i> , 2001, 15, 1764-1770.	0.2	22
128	The preferential involvement of extraocular muscles by myasthenia gravis. <i>Neuro-Ophthalmology</i> , 2001, 25, 219-228.	0.4	7
129	Autoantibody Testing in Neuromuscular Disorders, Part I. <i>Journal of Clinical Neuromuscular Disease</i> , 2000, 2, 84-95.	0.3	0
130	Autoantibody Testing in Neuromuscular Disorders, Part II. <i>Journal of Clinical Neuromuscular Disease</i> , 2000, 2, 96-105.	0.3	8
131	Eye muscle sparing by the muscular dystrophies: Lessons to be learned?. <i>Microscopy Research and Technique</i> , 2000, 48, 192-203.	1.2	53
132	Nitric oxide myotoxicity is age related. <i>Mechanisms of Ageing and Development</i> , 2000, 113, 183-191.	2.2	7
133	T cell recognition of muscle acetylcholine receptor in ocular myasthenia gravis. <i>Journal of Neuroimmunology</i> , 2000, 108, 29-39.	1.1	31
134	Autoantibodies in Thymoma-Associated Myasthenia Gravis With Myositis or Neuromyotonia. <i>Archives of Neurology</i> , 2000, 57, 527.	4.9	87
135	Treatment of Ocular Myasthenia. <i>Archives of Neurology</i> , 2000, 57, 752.	4.9	54
136	Myasthenia gravis: recommendations for clinical research standards ¹¹ Reprinted with permission from <i>Neurology</i> 2000;55:16-23 (© AAN Enterprises, Inc.). Additional material related to this article can be found on the Neurology Web site at www.neurology.org . Consult the Table of Contents for the July 12 issue to find the title link for this article. See also <i>Neurology</i> 2000;55:3-4, 7-15.. <i>Annals of Thoracic Surgery</i> , 2000, 70, 327-334.	0.7	414
137	Nitric oxide synthase in aging rat skeletal muscle. <i>Mechanisms of Ageing and Development</i> , 1999, 109, 177-189.	2.2	36
138	Neuromuscular transmission defect caused by carbamazepine ¹ . , 1999, 22, 1293-1296.		15
139	Heme oxygenase-2 expression at rat neuromuscular junctions. <i>Neuroscience Letters</i> , 1999, 273, 143-146.	1.0	14
140	Disorders of neuromuscular junction ion channels ¹¹ In collaboration with The American Physiological Society, Thomas E. Andreoli, MD, Editor. <i>American Journal of Medicine</i> , 1999, 106, 97-113.	0.6	62
141	Acetylcholine Receptor Epitopes in Ocular Myasthenia ^a . <i>Annals of the New York Academy of Sciences</i> , 1998, 841, 309-319.	1.8	18
142	Ryanodine receptor gene expression thymomas. , 1998, 21, 1299-1303.		19
143	ENDOCRINE NEUROMYOPATHIES. <i>Neurologic Clinics</i> , 1997, 15, 673-696.	0.8	35
144	Ocular muscle involvement by myasthenia gravis. <i>Annals of Neurology</i> , 1997, 41, 419-420.	2.8	35

#	ARTICLE	IF	CITATIONS
145	Nitric oxide synthase is concentrated at the skeletal muscle endplate. <i>Brain Research</i> , 1996, 730, 238-242.	1.1	91
146	Congenital Neuromuscular Diseases Presenting in Adulthood. <i>Seminars in Neurology</i> , 1996, 16, 47-54.	0.5	1
147	The Myasthenic Syndromes. , 1996, , 565-593.		11
148	Spinal cord histopathology in long-term survivors of poliomyelitis. <i>Muscle and Nerve</i> , 1995, 18, 1208-1209.	1.0	21
149	The gamma-Subunit of the Acetylcholine Receptor Is Not Expressed in the Levator Palpebrae Superioris. <i>Neurology</i> , 1995, 45, 516-518.	1.5	32
150	Pathological Analysis of Spinal Cords from Survivors of Poliomyelitis. <i>Annals of the New York Academy of Sciences</i> , 1995, 753, 390-393.	1.8	5
151	Intracranial Suppuration. <i>Neurosurgery</i> , 1994, 34, 974-981.	0.6	83
152	Central nervous system complications of cystosarcoma phyllodes. <i>Cancer</i> , 1993, 72, 126-130.	2.0	12
153	Acetylcholine receptor subunit gene expression in thymic tissue. <i>Muscle and Nerve</i> , 1993, 16, 1332-1337.	1.0	39
154	MYF-4 Does Not Mediate AChR Receptor Subunit mRNA Expression in Thymic Tissues. <i>Annals of the New York Academy of Sciences</i> , 1993, 681, 103-106.	1.8	0
155	Insights into Possible Skeletal Muscle Nicotinic Acetylcholine Receptor (AChR) Changes in Some Congenital Myasthenias from Physiological Studies, Point Mutations, and Subunit Substitutions of the AChR. <i>Annals of the New York Academy of Sciences</i> , 1993, 681, 435-450.	1.8	7
156	Relation of Aphemia and Agraphia. <i>European Neurology</i> , 1992, 32, 302-304.	0.6	3
157	Transient neurologic deficit caused by chronic subdural hematoma. <i>American Journal of Medicine</i> , 1992, 92, 698-700.	0.6	36
158	Congenital Disorders of Neuromuscular Transmission. <i>Hospital Practice (1995)</i> , 1992, 27, 73-85.	0.5	11
159	Extraocular muscles are spared in advanced duchenne dystrophy. <i>Annals of Neurology</i> , 1992, 32, 586-588.	2.8	114
160	Treatment of the Elderly Patient with Headache or Trigeminal Neuralgia. <i>Drugs and Aging</i> , 1991, 1, 48-56.	1.3	7
161	Ocular flutter and ataxia associated with AIDS-related complex. <i>Neuro-Ophthalmology</i> , 1991, 11, 163-167.	0.4	10
162	Spinal Epidural Abscess: A Ten-Year Perspective. <i>Neurosurgery</i> , 1990, 27, 177-184.	0.6	452

#	ARTICLE	IF	CITATIONS
163	Why are eye muscles frequently involved in myasthenia gravis?. <i>Neurology</i> , 1990, 40, 1663-1663.	1.5	120
164	<i>SECTION OF GEOLOGY AND MINERALOGY</i> : DEVELOPMENT OF THE U.S. NAVY'S ICE FORECASTING SERVICE, 1947â€“1953, AND ITS GEOLOGICAL IMPLICATIONS*. <i>Transactions of the New York Academy of Sciences</i> , 1954, 16, 162-174.	0.2	1